Drug Profile
Research programme: recombinant apolipoprotein AI - SemBioSys Genetics
Alternative Names: Apolipoprotein AI - SemBioSys Genetics; Apolipoprotein AI(Milano) - SemBioSys Genetics; Plant-derived apolipoprotein AI - SemBioSys GeneticsLatest Information Update: 04 May 2012
Price :
$50
*
At a glance
- Originator SemBioSys Genetics
- Class Apolipoprotein therapeutics; Recombinant proteins
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Cardiovascular disorders
Highest Development Phases
- Discontinued Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Stroke
Most Recent Events
- 30 Apr 2012 Discontinued - Preclinical for Acute coronary syndromes in Canada (Parenteral)
- 30 Apr 2012 Discontinued - Preclinical for Atherosclerosis in Canada (Parenteral)
- 30 Apr 2012 Discontinued - Preclinical for Cardiovascular disorders in Canada (Parenteral)